RICHARD D. MEYER, M.D.
Amikacin, the first semisynthetic aminoglycoside introduced for clinical use, has the widest spectrum of activity of these agents. This paper assesses new data on two-compartment pharmokinetics, intrathecal use, use of serum assay results, interactions with penicillins, and comparative studies of efficacy and toxicity. Indications for the use of amikacin and its role in the face of bacterial resistance to it or to other aminoglycosides are examined. The need for an agent active against most gram-negative bacilli in empiric therapy for suspected or documented bacteremia indicates the continuing importance of the aminoglycosides and, in immunocompromised patients, of amikacin.
Learn more about subscription options.
Register Now for a free account.
MEYER RD. Drugs Five Years Later: Amikacin. Ann Intern Med. 1981;95:328–332. doi: 10.7326/0003-4819-95-3-328
Download citation file:
Published: Ann Intern Med. 1981;95(3):328-332.
Emergency Medicine, Infectious Disease, Multi-Organ Failure and Sepsis, Pulmonary/Critical Care.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only